Hardy et al. [10] observed an association between plasma DNAm in the PPARγ gene promoter and severity of fibrosis in 26 NAFLD patients, ranging from mild (F0–F2) to severe fibrosis (F3–F4), and reported that an optimal cutoff of 81% DNAm was able to separate NAFLD patients with mild versus severe fibrosis with a sensitivity of 83% and a specificity of 93%, though prediction accuracy was not assessed in an independent dataset. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.